Search Results - "Modest, D.P."

Integration of retifanlimab into the standard of care first-line therapy of advanced squamous anal cancer—lessons learned and open questions.

Authors: Modest, D.P. Hofheinz, R.-D.

Source: Annals of Oncology. Aug2026, Vol. 37 Issue 8, p1028-1029. 2p.

Response to 'A temporal paradox in the proposed risk-adjusted surveillance algorithm for metastatic colorectal cancer'.

Authors: Germani, M.M. Modest, D.P.

Source: Annals of Oncology. Dec2025, Vol. 36 Issue 12, p1547-1548. 2p.

Treatment sequencing in metastatic colorectal cancer.

Authors: Modest, D.P. Pant, S. Sartore-Bianchi, A.

Source: European Journal of Cancer. Mar2019, Vol. 109, p70-83. 14p.

Surgical treatment options following chemotherapy plus cetuximab or bevacizumab in metastatic colorectal cancer—central evaluation of FIRE-3.

Authors: Modest, D.P. Denecke, T. Pratschke, J. et al.

Source: European Journal of Cancer. Jan2018, Vol. 88, p77-86. 10p.

Evaluation of survival across several treatment lines in metastatic colorectal cancer: Analysis of the FIRE-3 trial (AIO KRK0306).

Authors: Modest, D.P. Ricard, I. Stintzing, S. et al.

Source: European Journal of Cancer. Oct2017, Vol. 84, p262-269. 8p.

FOLFOXIRI plus bevacizumab as conversion-therapy for liver metastases in colorectal cancer: A necessity?

Authors: Modest, D.P. Neumann, U.P. Pratschke, J.

Source: European Journal of Cancer. Mar2017, Vol. 73, p71-73. 3p.

Metastatic colorectal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up.

Authors: Cremolini, C. Chalabi, M. Elez, E. et al.

Source: Annals of Oncology. Jun2026, Vol. 37 Issue 6, p759-776. 18p.

1301P Sequential therapy of metastatic pancreatic ductal adenocarcinoma (PDAC) after failure of gemcitabine plus nab-paclitaxel with either 5-FU/folinic acid (5FU/LV) plus irinotecan (FOLFIRI) followed by 5FU/LV plus oxaliplatin (OFF) or the reverse sequence: The PANTHEON trial (AIO PAK 0116)

Authors: Modest, D.P. Heinemann, V. Schütt, P. et al.

Source: Annals of Oncology. 2022 Supplement 7, Vol. 33, pS1139-S1139. 1p.

66P Targeted treatment (TT) after immune checkpoint inhibitors (ICIs) in BRAF V600E mutated (BRAFm) and deficient mismatch repair or microsatellite instability high (dMMR/MSI-H) metastatic colorectal cancer (mCRC).

Authors: Ambrosini, M. Tougeron, D. Modest, D.P. et al.

Source: Annals of Oncology. 2024 Supplement 1, Vol. 35, pS32-S32. 1p.

Impact of BRAF and RAS mutations on first-line efficacy of FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab: analysis of the FIRE-3 (AIO KRK-0306) study.

Authors: Stintzing, S. Miller-Phillips, L. Modest, D.P. et al.

Source: European Journal of Cancer. Jul2017, Vol. 79, p50-60. 11p.

436TiP COLSTAR: Randomized, open-label, multicentre, phase III study comparing futuximab/modotuximab plus trifluridine/tipiracil to trifluridine/tipiracil in KRAS/NRAS and BRAF wild type (wt) metastatic colorectal cancer (mCRC) previously treated with both standard and anti-EGFR treatment

Authors: Ciardiello, F. Yoshino, T. Modest, D.P. et al.

Source: Annals of Oncology. 2022 Supplement 7, Vol. 33, pS733-S734. 2p.

745P Estimating the clinical benefit of the secondary resection of metastases in liver-limited metastatic colorectal cancer: An individual patient data-based pooled analysis of nine randomized trials.

Authors: Taravella, A. Germani, M.M. Rossini, D. et al.

Source: Annals of Oncology. 2025 Supplement 2, Vol. 36, pS520-S521. 2p.

743P Combined analysis of overall survival (OS) from the phase III CodeBreaK 300 and phase Ib CodeBreaK 101 studies of sotorasib 960 mg plus panitumumab (soto960+pani) therapy for chemorefractory KRAS G12C-mutated metastatic colorectal cancer (mCRC).

Authors: Kuboki, Y. Pietrantonio, F. Salvatore, L. et al.

Source: Annals of Oncology. 2025 Supplement 2, Vol. 36, pS518-S519. 2p.

441P Evaluation of conversion therapy in patients undergoing secondary resection of metastases in curative intent within the FIRE-3 (AIO KRK-0306) study.

Authors: von Einem, J.C. Heinemann, V. Modest, D.P. et al.

Source: Annals of Oncology. 2020 Supplement 4, Vol. 31, pS429-S429. 1p.

357P ADJUBIL: A phase II study of durvalumab and tremelimumab with or without capecitabine in ADJUvant BILiary tract cancer: The IKF/AIO-ADJUBIL trial.

Authors: Goetze, T.O. Vogel, A. Gonzalez Carmona, M.A. et al.

Source: Annals of Oncology. 2025 Supplement 1, Vol. 36, pS140-S140. 1p.

321P Results of an open-label, single-arm phase II trial investigating the efficacy and safety of trifluridine/tipiracil combined with irinotecan as a second-line therapy in patients with cholangiocarcinoma (TRITICC).

Authors: Roderburg, C. Gonzalez Carmona, M.A. Berres, M-L. et al.

Source: Annals of Oncology. 2025 Supplement 1, Vol. 36, pS125-S125. 1p.

39P AntiEGFR-based maintenance versus stop&go strategy in patients with left-sided, non MSI, RAS/BRAF wild type (wt) metastatic colorectal cancer (mCRC): Individual patient data (IPD) pooled analysis of randomized clinical trials (RCTs).

Authors: Raimondi, A. Tinè, G. De Stefano, A. et al.

Source: Annals of Oncology. 2025 Supplement 1, Vol. 36, pS24-S24. 1p.

180P FIRE-6: Longitudinal immune profiling identified disturbed NK cell functionality in RAS/BRAF wild-type metastatic colorectal cancer patients and during combined treatment with FOLFIRI, cetuximab followed by avelumab maintenance.

Authors: Schiele, P. Kolling, S. Stintzing, S. et al.

Source: Annals of Oncology. 2024 Supplement 2, Vol. 35, pS287-S288. 2p.

506O Evaluation of risk of disease progression in first-line therapy of unresected metastatic colorectal cancer to guide intervals of radiological assessment: An analysis of eleven randomized trials by AIO and GONO.

Authors: Germani, M.M. Heinemann, V. Rossini, D. et al.

Source: Annals of Oncology. 2024 Supplement 2, Vol. 35, pS430-S431. 2p.

Relevance of baseline carcinoembryonic antigen for first-line treatment against metastatic colorectal cancer with FOLFIRI plus cetuximab or bevacizumab (FIRE-3 trial).

Authors: Holch, J.W. Ricard, I. Stintzing, S. et al.

Source: European Journal of Cancer. Jan2019, Vol. 106, p115-125. 11p.